bioRxivCancer Biology
MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies
S. Swaminathan, L. Heftdal, D. Liefwalker, R. Dhanasekaran, A. Deutzmann, C. Horton, A. Mosley, M. Libersbach, H. Maecker, D. Felsher
Abstract
The MYC oncogene drives T and B lymphoid malignancies, including Burkitts lymphoma (BL) and Acute Lymphoblastic Leukemia (ALL). Using CyTOF, we demonstrate a systemic reduction in natural killer (NK) cell-mediated surveillance in SR-tTA/Tet-O-MYCON mice bearing MYC-driven T-lymphomas, due to an arrest in NK cell maturation. Inactivation of lymphoma-intrinsic MYC releases the brakes on NK maturation restoring NK homeostasis. Lymphoma-intrinsic MYC arrests NK maturation by transcriptionally repressing STAT1/2 and secretion of Type I Interferons (IFNs). Treating T-lymphoma-bearing mice with Type I IFN improves survival by rescuing NK cell maturation. In MYC-driven BL patients, low expression of both STAT1 and STAT2 correlates significantly with the absence of activated NK cells and predicts unfavorable clinical outcomes. Adoptive transfer of mature NK cells is sufficient to delay both T-lymphoma growth and recurrence post MYC inactivation. Our studies thus provide a rationale for developing NK cell-based therapies to effectively treat MYC-driven lymphomas in the future.\n\nAbbreviations
- organism: mouse
- assay: flow cytometry
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapse
S. Tahri, M. M. E. de Jong, … T. Cupedo·bioRxiv·Jul 5, 2023
- Myc controls IL-15-driven expansion and translational machinery of NK cells
H. J. Khameneh, N. Fonta, … G. Guarda·bioRxiv·Dec 20, 2022
- The SUMOylation inhibitor TAK-981 (Subasumstat) triggers IFN-I-dependent activation of Natural Killer cells against Acute Myeloid Leukemias.
R. Hallal, M. De Toledo, … G. Bossis·bioRxiv·Feb 19, 2024
- Inflamed Natural Killer cells with adhesion defects are associated with a poor prognosis in Multiple Myeloma
E. Blanquart, R. Ekren, … L. Martinet·bioRxiv·Jan 15, 2024
- MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugs.
Hai Vu Nguyen, Marcel Michla, … Suzanne Cory·bioRxiv·May 1, 2026
- CD45 limits Natural Killer cell development from common lymphoid progenitors
L. G. Meza Guzman, C. D. Hyland, … N. Huntington·bioRxiv·Apr 17, 2023